Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. (Q30577903)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Matthew J Armstrong

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Jeremy W Tomlinson

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

author name string

D D Houlihan

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

I A Rowe

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

W H O Clausen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

B Elbrønd

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

S C L Gough

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

language of work or name

0 references

publication date

19 November 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

37

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

234-242

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Endpoints and clinical trial design for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Biology of incretins: GLP-1 and GIP

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Incretin mimetics as a novel therapeutic option for hepatic steatosis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled tr

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Updated definitions of healthy ranges for serum alanine aminotransferase levels

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review.

1 reference

https://api.crossref.org/works/10.1111%2FAPT.12149

21 January 2018

Identifiers

10.1111/APT.12149

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23163663%20AND%20SRC:MED&resulttype=core&format=json

18 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30577903&oldid=1548534720"